マーケットレポート詳細
コンパニオン動物向け医薬品の世界市場：2027年に至る適応症別、動物別予測
Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses), Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics, Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global Forecasts to 2027
- 出版元：MarketsandMarkets
出版元について - 発行年：2023年3月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文268ページになります。
- 商品コード：MAM3211
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
コンパニオン動物向け医薬品の世界市場規模は2022年で144億ドル、2027年に196億ドル、市場の平均年成長率は6.3%になると予測されています。
レポートはコンパニオン動物向け医薬品の世界市場について2027年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（適応症別市場、投与経路別市場、等）を中心に構成されています。また競合状況、主要企業情報（10社）、業界構造分析、エコシステム分析などの分析も加味し、コンパニオン動物向け医薬品市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆コンパニオン動物向け医薬品の世界市場予測2020-2027年
・市場規模(US$)
◆適応症別、市場-2027年
感染症
・寄生虫駆除剤
・ワクチン
・抗生物質/抗菌剤
・その他
皮膚疾患
疼痛
整形外科疾患
行動障害
その他適応症
※(市場規模US$)
◆投与経路別、市場-2027年
・経口投与
・非経口投与（注射）
・局所投与
※(市場規模US$)
◆動物タイプ別、市場-2027年
・犬
・猫
・馬
・その他コンパニオン動物
※(市場規模US$)
◆流通経路別、市場-2027年
・動物病院
・獣医クリニック
・小売薬局
※(市場規模US$)
◆主要国地域別市場-2027年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・スペイン、イタリア
・その他欧州
アジア太平洋
・日本、中国、インド
・韓国、オーストラリア
・その他アジア太平洋
中南米
中東アフリカ
※国地域別に全セグメントの細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス（促進要因、障壁、機会、課題）
・業界構造分析
・バリューチェーン分析
・サプライチェーン分析
・エコシステム分析
・特許分析
・プライシング分析
・貿易分析
・競合状況
・市場シェア分析
◆コンパニオン動物向け医薬品の主要企業プロフィール動向
・ZOETIS INC
・MERCK & CO, INC
・BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・ELANCO ANIMAL HEALTH INCORPORATED
・VIRBAC
・DECHRA PHARMACEUTICALS PLC
・VETOQUINOL
・NEOGEN CORPORATION
・ORION GROUP
・ECO ANIMAL HEALTH GROUP PLC
その他企業
・ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED
・NORBROOK
・CHANELLE PHARMA
・HIPRA
・CEVA SANTÉ ANIMALE
・TIANJIN RINPU BIO-TECHNOLOGY CO, LTD
・共立製薬株式会社
・ENDOVAC ANIMAL HEALTH
・INDIAN IMMUNOLOGICALS LTD
・ASHISH LIFE SCIENCE PVT LTD
・PHARMA PVT LTD
・BIOGENESIS BAGO SA
・INTAS PHARMACEUTICALS
・BRILLIANT BIOPHARMA
・VETINDIA PHARMACEUTICALS LIMITED
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.2.2 MARKETS COVERED 33
・ FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED 33
1.3 CURRENCY CONSIDERED
・ TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 REFINEMENTS IN SEGMENTS OF GLOBAL MARKET
1.6.2 UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS
1.6.3 UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS
1.6.4 ADDITION OF RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
・ FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY RESEARCH
2.1.1.1 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY RESEARCH 38
2.1.2.1 PRIMARY SOURCES
2.1.2.2 KEY DATA FROM PRIMARY SOURCES
2.1.2.3 KEY INDUSTRY INSIGHTS
2.1.2.4 BREAKDOWN OF PRIMARIES
・ FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
・ FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
・ FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS INC.
・ FIGURE 6 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS
・ FIGURE 7 MARKET ANALYSIS APPROACH
・ FIGURE 8 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH
・ FIGURE 9 TOP-DOWN APPROACH 46
・ FIGURE 10 CAGR PROJECTIONS
・ FIGURE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET (2022–2027): IMPACT ANALYSIS ON DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 DATA TRIANGULATION APPROACH
・ FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 IMPACT OF RECESSION
3 EXECUTIVE SUMMARY
・ FIGURE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
・ FIGURE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)
・ FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2022 VS. 2027 (USD MILLION)
・ FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION)
・ FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHICAL SNAPSHOT
4 PREMIUM INSIGHTS
4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW
・ FIGURE 18 INCREASING PREVALENCE OF ZOONOTIC DISEASES AND RISING PET OWNERSHIP RATES WORLDWIDE TO DRIVE MARKET
4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2021)
・ FIGURE 19 INFECTIOUS DISEASES SEGMENT IN GERMANY ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
・ FIGURE 20 CHINA & INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2022–2027)
・ FIGURE 21 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS 60
・ FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 RISING PREVALENCE OF ZOONOTIC DISEASES
・ TABLE 2 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2019)
5.2.1.2 RISING DEMAND FOR PET INSURANCE DUE TO GROWING ANIMAL HEALTH EXPENDITURE
・ TABLE 3 US: AVERAGE PREMIUM RATES (2019–2021)
・ FIGURE 24 CANADA: AVERAGE ANNUAL PREMIUMS (2017–2021)
・ TABLE 4 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2021 (USD MILLION)
5.2.1.3 INCREASING R&D INVESTMENTS FOR ANIMAL HEALTHCARE
5.2.1.4 RISING AWARENESS INITIATIVES BY GOVERNMENT AGENCIES AND ANIMAL WELFARE ORGANIZATIONS
5.2.1.5 HIGH PET OWNERSHIP RATES WORLDWIDE
・ TABLE 5 PET POPULATION, BY ANIMAL, 2014–2020 (MILLION)
・ TABLE 6 MARKET DRIVERS: IMPACT ANALYSIS
5.2.2 MARKET RESTRAINTS 68
5.2.2.1 RISING PET CARE COSTS
・ FIGURE 25 US: PET INDUSTRY EXPENDITURE, 2010–2020
5.2.2.2 LIMITED NUMBER OF NOVEL PHARMACEUTICALS FOR VETERINARY CARE
5.2.2.3 HIGH COST OF VACCINES AND COMPLEXITIES ASSOCIATED WITH STORAGE
5.2.2.4 GROWING RESISTANCE TO ANTIMICROBIALS AND ANTIBIOTICS
・ TABLE 7 MARKET RESTRAINTS: IMPACT ANALYSIS
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 LUCRATIVE GROWTH OPPORTUNITIES IN EMERGING MARKETS
5.2.3.2 GROWING PREVALENCE OF CHRONIC ANIMAL DISEASES
5.2.3.3 RISING TECHNOLOGICAL ADVANCEMENTS IN VACCINE MANUFACTURING
・ TABLE 8 MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.2.4 MARKET CHALLENGES 73
5.2.4.1 STRINGENT REGULATORY APPROVAL PROCESS FOR PHARMACEUTICALS
5.2.4.2 LIMITED AWARENESS OF VACCINE COVERAGE
5.2.4.3 MISDIAGNOSIS DUE TO DIVERSITY OF PARASITES
5.2.4.4 LOW ANIMAL HEALTHCARE EXPENDITURE IN EMERGING MARKETS
・ TABLE 9 MARKET CHALLENGES: IMPACT ANALYSIS
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
6.2.1 RISING ACQUISITIONS OF SMALLER COMPANIES BY GLOBAL PLAYERS
・ TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET: MAJOR ACQUISITIONS (2017–2022)
6.2.2 INCREASING PRODUCT INNOVATIONS FOR ANIMAL HEALTHCARE
・ TABLE 11 INNOVATIVE COMPANION ANIMAL PHARMACEUTICAL TRENDS
6.2.3 EXPANDING VETERINARY BUSINESSES WORLDWIDE
6.3 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 12 PORTER’S FIVE FORCES ANALYSIS
6.3.1 THREAT OF NEW ENTRANTS
6.3.2 THREAT OF SUBSTITUTES
6.3.3 BARGAINING POWER OF SUPPLIERS
6.3.4 BARGAINING POWER OF BUYERS
6.3.5 INTENSITY OF COMPETITIVE RIVALRY
6.4 REGULATORY ANALYSIS
・ FIGURE 26 COMPANION ANIMAL PHARMACEUTICAL MARKET: DEVELOPMENT AND APPROVAL PROCESS FOR PRODUCTS
・ TABLE 13 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS
・ FIGURE 27 COMPANION ANIMAL PHARMACEUTICAL MARKET: PRODUCT APPROVAL PROCESS IN EUROPE
6.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.1 US
・ TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.2 EUROPE
・ TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.3 REST OF THE WORLD
・ TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.5 VALUE CHAIN ANALYSIS
・ FIGURE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
6.6 SUPPLY CHAIN ANALYSIS
・ FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
6.7 ECOSYSTEM ANALYSIS
6.7.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
・ FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
6.8 PATENT ANALYSIS
6.8.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: PATENT ANALYSIS TRENDS
・ FIGURE 31 PATENT PUBLICATION TRENDS (JANUARY 2013–DECEMBER 2022)
6.8.2 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS
・ FIGURE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET: TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR PATENTS (2017–2022)
6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS
・ FIGURE 33 COMPANION ANIMAL PHARMACEUTICAL MARKET: TOP APPLICANT COUNTRIES FOR PATENTS (2017–2022)
6.9 PRICING ANALYSIS
・ TABLE 17 AVERAGE SELLING PRICES OF COMPANION ANIMAL PHARMACEUTICALS BY APPLICATION (USD)
6.10 KEY CONFERENCES AND EVENTS FROM 2023 TO 2024
・ TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET: CONFERENCES AND EVENTS
6.11 KEY STAKEHOLDERS & BUYING CRITERIA
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
・ FIGURE 34 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
・ TABLE 19 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
・ FIGURE 35 BUYING CRITERIA
・ TABLE 20 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
6.12 TRADE ANALYSIS
7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION
7.1 INTRODUCTION
・ TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
7.2 INFECTIOUS DISEASES
・ TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 PARASITICIDES
7.2.1.1 GROWING REGULATORY GUIDELINES TO CONTROL PARASITE-RELATED DISEASES TO FUEL MARKET
・ TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
7.2.2 VACCINES
7.2.2.1 GROWING AWARENESS AMONG PET OWNERS FOR CANINE & FELINE VACCINES TO DRIVE MARKET
・ TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 ANTIBIOTICS AND ANTIMICROBIALS
7.2.3.1 EFFECTIVE PREVENTION FOR CLINICAL AND SUBCLINICAL DISEASES IN COMPANION ANIMALS TO FUEL UPTAKE
・ TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 OTHERS
・ TABLE 27 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 DERMATOLOGIC DISEASES
7.3.1 RISING CASES OF DERMATITIS DUE TO NUTRITIONAL DEFICIENCIES TO DRIVE MARKET
・ TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 PAIN
7.4.1 RISING DEMAND FOR ANTI-INFLAMMATORY DRUGS AND OPIOIDS TO DRIVE MARKET
・ TABLE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 ORTHOPEDIC DISEASES
7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS DUE TO INCREASING OBESITY IN PETS TO DRIVE MARKET
・ TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 BEHAVIORAL DISORDERS
7.6.1 INCREASING AWARENESS AMONG PET OWNERS FOR APPROPRIATE PET BEHAVIOR TO SUPPORT MARKET GROWTH
・ TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.7 OTHER INDICATIONS
・ TABLE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
・ TABLE 33 ROUTES OF ADMINISTRATION FOR KEY COMPANION ANIMAL PHARMACEUTICALS
・ TABLE 34 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
8.2 ORAL ADMINISTRATION
8.2.1 ABILITY TO TREAT A WIDE RANGE OF DISEASES AND AFFORDABILITY OF MEDICATION TO DRIVE DEMAND 116
・ TABLE 35 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 INJECTABLE ADMINISTRATION
8.3.1 ADVANTAGES OF COMPLETE ABSORPTION AND BIOAVAILABILITY TO FUEL MARKET
・ TABLE 36 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INJEC・ TABLE ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 TOPICAL ADMINISTRATION
8.4.1 TEMPORARY EFFECTS OF TOPICAL DRUGS COMPARED TO ORAL AND PARENTERAL DRUGS TO RESTRAIN MARKET 118
・ TABLE 37 COMPANION ANIMAL PHARMACEUTICAL MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE
9.1 INTRODUCTION
・ TABLE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
9.2 DOGS
9.2.1 RISING PET DOG POPULATION WORLDWIDE TO DRIVE MARKET
・ FIGURE 36 GROWING PET DOG POPULATION IN INDIA (MILLION)
・ FIGURE 37 POPULATION OF PET DOGS GLOBALLY (MILLION)
・ TABLE 39 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CATS
9.3.1 INCREASING R&D ACTIVITIES ON FELINE HEALTH TO DRIVE MARKET
・ TABLE 40 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 HORSES
9.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
・ TABLE 41 HORSE POPULATION, BY REGION, 2016–2020 (MILLION)
・ TABLE 42 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 OTHER COMPANION ANIMALS
・ TABLE 43 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)
10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL
10.1 INTRODUCTION
・ TABLE 44 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
10.2 VETERINARY HOSPITALS
10.2.1 GROWING FOCUS ON HEALTHCARE AND COMPANION ANIMAL DIAGNOSTIC SERVICES TO DRIVE MARKET
・ TABLE 45 VETERINARY VISIT EXPENSES FOR CATS AND DOGS (US)
・ TABLE 46 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 VETERINARY CLINICS
10.3.1 RISING NUMBER OF PRIVATE CLINICAL PRACTICES TO DRIVE MARKET
・ TABLE 47 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY (2019 VS. 2021)
・ TABLE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 RETAIL PHARMACIES
10.4.1 ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTIONS AND OTC MEDICATION TO SUPPORT MARKET GROWTH
・ TABLE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2027 (USD MILLION)
11 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION
11.1 INTRODUCTION
・ TABLE 50 COMPANION ANIMAL POPULATION, BY COUNTRY, 2022 (THOUSAND)
・ FIGURE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
・ TABLE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
・ FIGURE 39 EXPECTED GROWTH FOR NUMBER OF VETERINARIANS IN NORTH AMERICA (2012 VS. 2030)
11.2.1 NORTH AMERICA: RECESSION IMPACT
・ FIGURE 40 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
・ TABLE 52 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 53 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 54 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 55 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 56 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 57 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.2.2 US
11.2.2.1 RISING PET EXPENDITURE TO FUEL MARKET
・ FIGURE 41 US: POPULATION OF DOGS, 2012–2020 (MILLION)
・ FIGURE 42 US: EXPENDITURE ON VET VISITS, 2013–2020
・ TABLE 58 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2019–2021
・ TABLE 59 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 60 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 61 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 62 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 63 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 146
11.2.3 CANADA
11.2.3.1 INCREASING PET OWNERSHIP RATES TO DRIVE DEMAND FOR VACCINES
・ TABLE 64 CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION)
・ TABLE 65 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 66 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 67 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 68 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 69 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 148
11.3 EUROPE
・ TABLE 70 EUROPE: COMPANION ANIMAL POPULATION, 2021 (MILLION)
・ TABLE 71 EUROPE: NUMBER OF VETERINARIANS, 2014–2020
11.3.1 EUROPE: RECESSION IMPACT
・ TABLE 72 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 73 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 74 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 75 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 76 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 77 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 152
11.3.2 GERMANY
11.3.2.1 RISING FOCUS ON ANIMAL HEALTH DUE TO INCREASING VET PRACTICES TO DRIVE MARKET
・ TABLE 78 GERMANY: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)
・ TABLE 79 GERMANY: NUMBER OF VETERINARIANS, 2015 VS. 2020
・ TABLE 80 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 81 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 82 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 83 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 84 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.3 UK
11.3.3.1 AVAILABILITY OF ANIMAL HEALTH INSURANCE POLICIES TO FUEL MARKET FOR PHARMACEUTICALS
・ TABLE 85 UK: COMPANION ANIMAL POPULATION, 2017–2020 (MILLION)
・ TABLE 86 UK: NUMBER OF VETERINARIANS, 2016 VS. 2020
・ TABLE 87 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 88 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 89 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 90 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 91 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 157
11.3.4 FRANCE
11.3.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR ANIMAL HEALTH PRODUCTS
・ TABLE 92 FRANCE: COMPANION ANIMAL POPULATION, 2010–2021 (MILLION)
・ TABLE 93 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 94 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 95 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 96 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 97 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 160
11.3.5 SPAIN
11.3.5.1 INCREASING ADOPTION RATES OF DOGS AND CATS TO FUEL MARKET
・ TABLE 98 SPAIN: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)
・ TABLE 99 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 100 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 101 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 102 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 103 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.6 ITALY
11.3.6.1 LUCRATIVE ANIMAL AND PET HEALTH SECTORS TO DRIVE MARKET GROWTH
・ TABLE 104 ITALY: PET POPULATION, 2017–2021 (MILLION)
・ TABLE 105 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 106 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 107 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 108 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 109 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
・ TABLE 110 REST OF EUROPE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)
・ TABLE 111 REST OF EUROPE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2019 VS. 2020
・ TABLE 112 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 113 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 114 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 115 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 116 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 168
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
・ FIGURE 43 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
・ TABLE 117 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 118 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 119 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 120 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 121 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 122 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 171
11.4.2 CHINA
11.4.2.1 RISING NUMBER OF ZOONOTIC & INFECTIOUS DISEASES IN ANIMALS TO DRIVE MARKET
・ FIGURE 44 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
・ TABLE 123 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 124 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 125 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 126 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 127 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 RISING DEMAND FOR IMPORTED BREEDS TO SUPPORT MARKET GROWTH
・ TABLE 128 JAPAN: DOMESTICATED DOG AND CAT POPULATION, 2012–2020 (THOUSAND)
・ TABLE 129 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 130 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 131 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 132 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 133 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.4 INDIA
11.4.4.1 RISING FOCUS ON PET CARE DUE TO A LARGE POPULATION OF DOMESTICATED ANIMALS TO DRIVE MARKET
・ FIGURE 45 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
・ TABLE 134 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 135 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 136 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 137 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 138 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 PET CARE INITIATIVES FOR STREET DOGS AND CATS TO FUEL MARKET FOR ANIMAL CARE PRODUCTS
・ TABLE 139 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 140 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 141 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 142 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 143 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 182
11.4.6 AUSTRALIA
11.4.6.1 GROWING AWARENESS OF PARASITIC INFECTIONS TO DRIVE DEMAND FOR PARASITICIDES
・ FIGURE 46 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
・ TABLE 144 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 145 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 146 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 147 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 148 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
・ TABLE 149 REST OF ASIA PACIFIC: NUMBER OF VETERINARIANS, 2012−2021
・ TABLE 150 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 151 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 152 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 153 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 154 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 GROWING POOL OF SKILLED VETERINARIANS OWING TO RISING PET POPULATION TO DRIVE MARKET
・ TABLE 155 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICA (2016 VS. 2019)
11.5.2 LATIN AMERICA: RECESSION IMPACT
・ TABLE 156 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 157 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 158 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 159 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 160 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 190
11.6 MIDDLE EAST & AFRICA
11.6.1 EMERGING MARKET FOR ANIMAL HEALTHCARE PRACTISES TO SUPPORT UPTAKE
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
・ TABLE 161 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
・ TABLE 162 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 163 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
・ TABLE 164 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
・ TABLE 165 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
・ FIGURE 47 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS (2019–2022)
12.2 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS
・ FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET: REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2017–2021)
12.3 MARKET SHARE ANALYSIS
・ FIGURE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER (2021)
12.4 COMPANY EVALUATION QUADRANT
12.4.1 STARS
12.4.2 EMERGING LEADERS 199
12.4.3 PERVASIVE PLAYERS 199
12.4.4 PARTICIPANTS
・ FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPANY EVALUATION QUADRANT (2021)
12.5 EVALUATION QUADRANT FOR STARTUPS/SMES
12.5.1 PROGRESSIVE COMPANIES
12.5.2 DYNAMIC COMPANIES 201
12.5.3 STARTING BLOCKS 201
12.5.4 RESPONSIVE COMPANIES
・ FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: STARTUPS/SME EVALUATION QUADRANT (2021)
12.6 COMPETITIVE BENCHMARKING
・ TABLE 166 COMPANION ANIMAL PHARMACEUTICALS MARKET: INDICATION PORTFOLIO ANALYSIS:
・ TABLE 167 COMPANION ANIMAL PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION PORTFOLIO ANALYSIS
・ TABLE 168 COMPANION ANIMAL PHARMACEUTICALS MARKET: ANIMAL TYPE PORTFOLIO ANALYSIS
・ TABLE 169 COMPANION ANIMAL PHARMACEUTICALS MARKET: DISTRIBUTION CHANNEL PORTFOLIO ANALYSIS
12.7 COMPANY GEOGRAPHIC FOOTPRINT
・ TABLE 170 COMPANION ANIMAL PHARMACEUTICALS MARKET: REGIONAL REVENUE MIX
12.8 COMPETITIVE SITUATION AND TRENDS
12.8.1 PRODUCT LAUNCHES & APPROVALS
・ TABLE 171 PRODUCT LAUNCHES & APPROVALS
12.8.2 DEALS
・ TABLE 172 DEALS
12.8.3 OTHER DEVELOPMENTS
・ TABLE 173 OTHER DEVELOPMENTS
13 COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS))*
13.1 KEY PLAYERS
13.1.1 ZOETIS INC.
・ TABLE 174 ZOETIS INC.: BUSINESS OVERVIEW
・ FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2021)
13.1.2 MERCK & CO., INC.
・ TABLE 175 MERCK & CO., INC.: BUSINESS OVERVIEW
・ FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・ TABLE 176 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
・ FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2021)
13.1.4 ELANCO ANIMAL HEALTH INCORPORATED
・ TABLE 177 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW
・ FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2021)
13.1.5 VIRBAC
・ TABLE 178 VIRBAC: BUSINESS OVERVIEW
・ FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2021)
13.1.6 DECHRA PHARMACEUTICALS PLC
・ TABLE 179 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW
・ FIGURE 57 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2021)
13.1.7 VETOQUINOL
・ TABLE 180 VETOQUINOL: BUSINESS OVERVIEW
・ FIGURE 58 VETOQUINOL: COMPANY SNAPSHOT (2021)
13.1.8 NEOGEN CORPORATION
・ TABLE 181 NEOGEN CORPORATION: BUSINESS OVERVIEW
・ FIGURE 59 NEOGEN CORPORATION: COMPANY SNAPSHOT (2021)
13.1.9 ORION GROUP
・ TABLE 182 ORION GROUP: BUSINESS OVERVIEW
・ FIGURE 60 ORION GROUP: COMPANY SNAPSHOT (2021)
13.1.10 ECO ANIMAL HEALTH GROUP PLC
・ TABLE 183 ECO ANIMAL HEALTH GROUP PLC: BUSINESS OVERVIEW
・ FIGURE 61 ECO ANIMAL HEALTH GROUP PLC: COMPANY SNAPSHOT (2021)
13.2 OTHER PLAYERS
13.2.1 ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED
13.2.2 NORBROOK
13.2.3 CHANELLE PHARMA 256
13.2.4 HIPRA
13.2.5 CEVA SANTÉ ANIMALE
13.2.6 TIANJIN RINPU BIO-TECHNOLOGY CO., LTD.
13.2.7 KYORITSU SEIYAKU 260
13.2.8 ENDOVAC ANIMAL HEALTH
13.2.9 INDIAN IMMUNOLOGICALS LTD.
13.2.10 ASHISH LIFE SCIENCE PVT. LTD.
13.2.11 PHARMA PVT. LTD. 263
13.2.12 BIOGENESIS BAGO S.A.
13.2.13 INTAS PHARMACEUTICALS
13.2.14 BRILLIANT BIOPHARMA
13.2.15 VETINDIA PHARMACEUTICALS LIMITED
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS) MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.